Autres langues Tarsus Pharmaceuticals, Inc.

Actions

TARS

US87650L1035

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 05/08/2026			Varia. 5j.	Varia. 1 janv.
61,29 ^USD	+0,29%		+4,73%	-25,15%

13:43	Tarsus renforce son portefeuille dans l'ophtalmologie avec l'acquisition d'Alkeus pour un montant allant jusqu'à 800 millions de dollars	RE
13:41	Flash résultats (TARS) : Tarsus Pharmaceuticals, Inc. publie un chiffre d'affaires de 173,9 millions de dollars au deuxième trimestre, contre une estimation FactSet de 169,7 millions de dollars	MT

Autres langues

13:43	Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
13:41	Earnings Flash (TARS) Tarsus Pharmaceuticals, Inc. Reports Q2 Revenue $173.9M, vs. FactSet Est of $169.7M
13:03	Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
13:03	Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
13:03	Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
02:03	Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
15/07	RxSight Names Aziz Mottiwala as CEO
13/07	Tarsus Pharmaceuticals, Inc. Announces Management Changes, Effective July 13, 2026
13/07	Tarsus Pharmaceuticals Appoints Neera Clase as Interim Chief Commercial Officer
13/07	Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
08/07	Tarsus Pharmaceuticals Buys iRenix Medical
08/07	Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
08/07	Tarsus Pharmaceuticals, Inc. completed the acqusisition of iRenix Medical, Inc.
08/07	Tarsus Pharmaceuticals, Inc. agreed to acquire iRenix Medical, Inc for approximately $570 million.
01/07	Tarsus Pharmaceuticals Faces Medicare Copay Allegations From Culper Research; Shares Fall
28/05	Tarsus to Participate in Upcoming Investor Conferences
14/05	Tarsus and John Cena partner to raise awareness of Demodex blepharitis, a common eyelid disease affecting approximately 25 million Americans
14/05	Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
07/05	Tarsus to Participate in Upcoming Investor Conferences
07/05	Tarsus Pharmaceuticals : Reports First Quarter 2026 Financial Results and Recent Business Achievements
07/05	Tarsus Pharmaceuticals : First Quarter 2026 Earnings Presentation
06/05	Earnings Flash (TARS) Tarsus Pharmaceuticals, Inc. Reports Q1 Revenue $162.1M, vs. FactSet Est of $149.6M
06/05	Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
06/05	Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
29/04	Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026